Clinical Efficacy and Outcomes of Remibrutinib (LOU064) in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines: Findings from a Phase IIb Study-Reference-Cited by-同舟云学术

Clinical Efficacy and Outcomes of Remibrutinib (LOU064) in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines: Findings from a Phase IIb Study

Published:2022-10-20 Issue: Volume: Page:32-39
ISSN:2054-6211
Container-title:EMJ Dermatology
language:
Short-container-title:EMJ Dermatol

Author:

Maurer Marcus,Giménez-Arnau Ana,Metz Martin,Fielden Claire

Abstract

As part of the 31st European Academy of Dermatology and Venereology (EADV) Annual Congress held in Milan, Italy, and online, 7th–10th September 2022, five poster presentations outlined results from the Phase IIb study of remibrutinib (LOU064) in patients with chronic spontaneous urticaria inadequately controlled with H1-antihistamines. These posters presented data on quality of life, the need for antihistamine rescue medication to address symptoms, the time to complete urticaria control, and the safety profile of remibrutinib. The findings were outlined in these poster presentations and are summarised here.

Publisher

European Medical Group

Subject

General Medicine

Reference23 articles.

1. Zuberbier T et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy. 2006;61(3):321-31.

2. Maurer M et al. Urticaria: Collegium Internationale Allergologicum (CIA) update 2020. Int Arch Allergy Immunol. 2020;181(5):321-33.

3. Zuberbier T et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-66.

4. Maurer M et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005-16.

5. Maurer M et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy. 2019;49(5):655-62.